Articles tagged with Drug Combinations
Researchers at the University of Pennsylvania have discovered a unique combination of hormone-based drugs that can produce enhanced weight loss in obese animals. The study found that cycling through different drug therapies over a month led to greater body weight loss compared to single-drug treatments.
Currently available drugs may be used alone or in combination to treat infectious diseases, addressing a pressing need due to slow development of new therapies. Non-profit entities and private industry collaboration is crucial for discovering novel interventions to combat drug-resistant pathogens.
A phase III clinical trial showed that combining lesinurad with febuxostat was more effective at lowering blood urate levels than febuxostat alone. The combination group achieved target urate levels in significantly more patients over 12 months.
A new study by University of Florida researcher Kalyani Sonawane finds that fixed-dose combination therapy associated with lower follow-up doctor visits and hospitalizations. Patients on this therapy are more likely to continue taking their medication as directed, resulting in significant cost savings.
Scientists have created a library of 308 compounds to test drug combinations for new therapies. A study found a synergy between flutamide and phenprocoumon that efficiently killed prostate cancer cells, targeting the androgen receptor. The CLOUD library is ideal for discovering new applications for approved active ingredients.
A study published in Journal of General Internal Medicine found that fixed-dose combination pills work best to encourage patients with high blood pressure to stick to their prescribed anti-hypertensive medications. Patients on these combined pills were 9% more likely to be persistent in taking their medication, compared to those on sin...
Scientists found that models with only two variables work best in combining drugs, reducing the risk of overfitting. The algorithm can be used to optimize various types of drug combinations, including those with multiple biological molecules.
A small study found that cancer patients treated with chemotherapy combination ABVD had more non-growing eggs in their ovaries, increasing the possibility of future fertility. Researchers believe further research is needed to understand this phenomenon.
A combination of formoterol and budesonide found to be safe and effective in treating moderate to severe asthma, with a lower risk of exacerbations than single-therapy budesonide. The therapy showed no significant increase in serious adverse events, providing reassurance for healthcare providers.
Scientists developed a novel algorithm to predict synergistic antifungal drug combinations for treating drug-resistant fungal infections. The algorithm, NLLSS, integrates various information types and experimentally validated 7 out of 13 predicted combinations for Candida albicans, providing new treatment options.
A new study by bioengineers at Brigham and Women's Hospital demonstrates the effectiveness of combination therapies in eliminating cancer cells. By pairing chemotherapy drug docetaxel with a targeted PI3K inhibitor, researchers achieved greater tumor inhibition and eliminated evidence of resistance.
Scientists at Stanford University have revived an abandoned drug that shows promise in fighting two disease-causing viruses, dengue and VEEV. The drug works by boosting the human body's ability to resist viruses rather than directly targeting them.
Researchers at UCLA and Shanghai Jiao Tong University have developed a new feedback system control technique to pinpoint the best possible drug-dose ratios for treating tuberculosis. This approach has identified promising combination treatments that can kill bacteria much faster than standard regimens, potentially shortening treatment ...
A new study found that one in six older adults now regularly use potentially deadly combinations of prescription and over-the-counter medications and dietary supplements. The study identified 15 potentially life-threatening drug combinations, with nearly half involving nonprescription medications or supplements.
Researchers from Kumamoto University used a new analysis system to evaluate the effectiveness of antithrombotic drugs in preventing and curing diseases caused by blood clots. The T-TAS system was able to accurately measure blood clotting ability, enabling healthcare providers to make informed decisions about medication management.
A Georgetown University Medical Center researcher is leading a multi-institutional effort to investigate the causes of rising drug-resistant malaria parasites. The study aims to understand molecular mechanisms responsible for this increasing resistance and develop new therapies.
Researchers have discovered a new combination of drugs that may be effective against resistant, BRAF-mutant melanoma by targeting different signaling pathways. The combination showed synergistic effects in tumors resistant to BRAF inhibition.
Researchers found that the combination therapy improved progression-free survival across various sub-groups, including those with poor prognostic factors. The study also showed similar efficacy regardless of BRAF mutation status and disease stage.
A 10-week randomized trial showed significantly reduced measures of agitation in patients treated with dextromethorphan-quinidine, with an average 51% reduction compared to placebo. The combination medication was associated with a lower risk of adverse events and cognitive impairment.
Researchers at Johns Hopkins Medicine discovered a protein-signaling process that accelerates the work of the most frequently mutated gene in adult leukemia. A combination of two drugs targeting this process and the gene itself slowed leukemia cell growth in mice, suggesting potential for improved treatment outcomes.
Associate Professor Suetonia Palmer's study provides an evidence-based guide on safe and effective blood-pressure-lowering drugs for patients with kidney disease and diabetes. The research, published in the Lancet journal, compared hundreds of studies to identify the most effective treatments.
Researchers found that imperfect drug penetration can lead to spatial monotherapy and rapid evolution of multidrug resistance. To combat this, doctors should consider drug combinations that reach similar parts of the body, potentially leaving pockets without any drugs.
A study by Queen Mary University of London found that over two-thirds of anti-depressant/benzodiazepine FDC sales and more than a quarter of NSAID FDC sales were from unapproved formulations. The researchers urge the Indian government to overhaul its drug regulatory system to prioritize patient safety.
A patented technology called CIVO enables simultaneous testing of multiple cancer drugs in a patient's tumor, accurately predicting systemic response. This innovation has shown positive findings using multiple cancer drugs tested in xenografted mouse models and canine patients.
Researchers have developed a multifaceted approach to identify drug combinations that reverse HIV-1 latency. Several 2-drug combinations were found to be able to reactivate HIV-1 without triggering an inflammatory response, and a model was created to correlate changes in viral RNA with virus secretion from T cells.
A new platform developed by UCLA bioengineers uses nanotechnology-enhanced medications and AI-driven analysis to create safer and more effective treatments for drug-resistant tumors. The approach, called Feedback System Control.II, has been shown to outperform traditional combination therapies.
Researchers developed a 3D-printed carrier that retains its shape and integrity, delivering immunosuppressive drug cyclosporine A and cells for local and sustained release. The system overcomes existing delivery limitations, providing a promising solution for treating diseases requiring cell-based therapy.
A randomized clinical trial compared the safety and effectiveness of combination therapy with rifapentine and isoniazid to treatment only with isoniazid. The study found that combination therapy was as effective in preventing TB in children, with zero cases reported in the combination group compared to three in the isoniazid-only group.
Researchers have identified a potential universal therapeutic target for treating multiple infections, including Ebola, by targeting the GRP78 protein. The OSU-03012 (AR-12) and FDA-approved Phosphodiesterase 5 Inhibitors combination has shown promise in preventing viral replication, killing cancer cells, and reducing antibiotic-resist...
Researchers at Saint Louis University discover a family of enzyme inhibitors that can suppress herpes simplex virus replication. The findings offer hope for new treatments that can work in combination with existing medications to completely suppress the virus.
Researchers found that a combination of specialist behavioral support and medication significantly increases the odds of smoking cessation success, with a 23% quit rate among study participants. The approach outperformed unaided quitting and nicotine replacement therapy alone.
A two-year clinical trial found that long-term use of a drug combination reduces the risk of recurrent urinary tract infection by up to 80% in children with vesicoureteral reflux. Children with bladder and bowel dysfunction saw the greatest reduction, up to an 80% lower risk of recurrent infections.
A study found that combination therapy with varenicline and bupropion resulted in better smoking abstinence rates at 12 weeks compared to monotherapy, but not at one year. After one year, the rates were similar, indicating that combination therapy may not provide a significant long-term benefit for smoking cessation.
The UCSF Global Health Group will conduct research on community-based strategies to identify and clear the last remaining malaria parasites in areas close to elimination. The goal is to determine risk factors associated with malaria transmission and explore effective interventions for high-risk groups.
A new study at Columbia University's Mailman School of Public Health found that drivers who test positive for drugs are three times more likely to be involved in a fatal crash. The study also showed that the combination of alcohol and drugs increases the risk by 23 times, making drugged driving a critical safety issue.
Researchers at the University of Minnesota Academic Health Center have developed a new delivery system for a combination of two FDA-approved drugs that may serve as an effective treatment for HIV. The discovery allows for a pill-form combination of decitabine and gemcitabine, marking a major step forward in patient feasibility.
A combination of two FDA-approved osteoporosis drugs, denosumab and teriparatide, was found to increase bone density more effectively than single-drug therapy in a small clinical trial. The treatment produced significant improvements in bone mineral density at multiple measured sites, including the lumbar spine and hip.
Researchers at Dartmouth-Hitchcock's Norris Cotton Cancer Center have found an innovative drug combination that targets the stubborn CLL cells. The combination of gossypol and navitoclax has shown to be effective in killing CLL cells, offering a new hope for patients with this disease.
Researchers found that a Bortezomib/Vorinostat combination therapy reactivated virus-induced cell lysis and induced PEL cell death, increasing the lifespan of mice with PEL tumors. This treatment combination could potentially be beneficial for immunocompromised patients with KSHV-associated malignancies.
Phase I and II trials of combining drugs to treat melanoma, including dabrafenib and trametinib, demonstrate a clinically meaningful improvement in progression-free survival, response rate, and duration of response. These studies suggest the potential for new drug combinations to delay resistance to BRAF inhibitors.
A new study found that cooking with a blend of sesame and rice bran oils significantly lowers blood pressure and improves cholesterol levels. The researchers discovered that the oil blend works nearly as well as a commonly prescribed high blood pressure medication, with even more impressive results when used in combination.
A new collaboration between DNDi and Cipla aims to develop a 4-in-1 ARV combination product for young children with HIV/AIDS, addressing the gap in current treatments. The goal is to provide safe, potent, child-friendly treatment combinations to accelerate care provision for infants and toddlers living with HIV/AIDS.
A study of 2,588 Finnish schizophrenic patients found that antidepressive treatment reduced mortality risk by 43%, whereas bensodiazepine use increased the risk of early death and suicide by 91%. The researchers also found no association between taking multiple antipsychotics and increased mortality.
A study published in the Anesthesia-Analgesia Journal found that Pressure Right's acupressure device enhanced the efficacy of a popular antiemetic drug combination in reducing PONV among high-risk patients. The device resulted in higher patient satisfaction and lower emesis rates compared to a sham device.
A study by Vall d'Hebron Institute of Oncology reveals a potential new strategy to boost efficacy and break down resistance in patients with HER2 positive breast cancer. The combination of two drugs shows promise as a third treatment option, offering hope for patients with advanced tumours.
The BWH Center for LAM Research and Clinical Care has been awarded a four-year grant to conduct a phase I clinical trial testing the safety and efficacy of a combination of hydroxychloroquine and sirolimus in treating LAM. This is the first time this drug combination has been tested in women with LAM.
A combination of lamotrigine and valproate significantly reduced seizure frequency in patients with very difficult-to-control epilepsy. The treatment regimen, out of 32 tested combinations, showed superior efficacy compared to other regimens.
Three artemisinin-based combination therapies were found to be highly effective in clearing the Plasmodium falciparum parasite in African children. DHAPQ was shown to have the longest post-treatment prophylaxis, making it a valid third option for treatment.
Researchers at the University of Manchester have developed a computer program that can rapidly identify ideal drug combinations to prevent inflammation and combat severe diseases. By analyzing billions of potential combinations, they hope to create tailored therapies for conditions such as stroke, cancer, and Alzheimer's.
A new drug combination of fludarabine and alemtuzumab significantly increases progression-free survival and prolongs the lives of patients with chronic lymphocytic leukemia (CLL). The treatment spares patients from toxicities and offers a more convenient dosing schedule.
A commentary in New England Journal of Medicine suggests fibrates do not lower heart risk in diabetic patients taking statins; doctors recommend prescription only to high-risk patients after optimal LDL control achieved
Researchers have developed super-mini vehicles that can carry drugs and imaging agents into the body, revolutionizing medicine by improving drug solubility and bio-distribution. The devices use self-assembling nano-sized structures to cross membrane barriers and enable combination therapies.
A new two-drug combination of phentermine and topiramate achieves more than double the weight loss of orlistat and compares favorably with emerging drugs. The treatment also improves blood pressure, lipids, glycaemia, and inflammatory markers.
Researchers found that hospitals with low AMI mortality rates shared an overall vision of excellence and had more senior management involvement, broad staff presence, and better communication among physicians. A new low-radiation alternative to CT angiography also shows promise in diagnosing coronary artery disease, with good specifici...
Researchers have found a new drug combination that enhances anti-tumor efficacy and protects the heart from damage caused by doxorubicin, a powerful anti-cancer drug. The combination of Viagra and doxorubicin significantly reduces tumor size in prostate cancer patients without harming healthy cells.
A study published in PLoS One suggests that minocycline plus N-acetylcysteine may be a valuable treatment for traumatic brain injury. Researchers at SUNY Downstate Medical Center found a synergistic improvement of cognition and memory after experimental traumatic brain injury, and are planning to bring this combination to clinical trials.
A recent study by researchers at UCLA Health Sciences has found that over a third of drinkers aged 60 and older consume excessive amounts of alcohol, posing health risks. The study also highlights demographic factors, such as age, education level, and income, that contribute to at-risk drinking among the elderly.
A new investigational treatment, DMQ, has been shown to effectively control pseudobulbar affect (PBA) in patients with multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS). The study found a significant improvement in test scores after 12 weeks of treatment.
A recent study from UT Southwestern Medical Center found that combination therapy yielded better results than individual drugs in treating enlarged prostate. The treatment, which combined dutasteride and tamsulosin, reduced the risk of BPH progression by 25% and PSA levels by 50%.
Researchers at Michigan Medicine have developed a combination drug that regulates the release of morphine and its antagonist, improving pain management for patients with chronic illnesses. The nanoparticle-based system uses a pro drug to sense oxygen levels and trigger the release of Naloxone, allowing for safer treatment in combat zones.